Medical Research Future Fund Action Group states support at Australian Senate inquiry

15 July 2015
2019_biotech_test_vial_discovery_big

The Medical Research Future Fund (MRFF) Action Group has stated its support at the Australian Senate’s inquiry into the MRFF Bill 2015 for a number of key aspects of the bill and proposed some minor amendments.

In a submission to the Senate Community Affairs Legislation Committee Inquiry, the action group welcomed the establishment of an Australian Medical Research Advisory Board, enabling expert guidance to be considered by the Health Minister in determining financial assistance to be paid from the MRFF.

The group was established in August 2014 to advocate for the extraordinary impact the MRFF would have on Australia’s health and prosperity, and its members come from a cross-section of the health and medical research community. It endorsed the flexibility of the MRFF Bill around the administration and allocation of financial assistance from the fund.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology